- 膵癌の再発とインスリン
267 ：がんと闘う名無しさん[sage]：2015/05/07(木) 15:45:43.52 ID:GaBkbFrK - ( ´,_ゝ`)ﾌﾟｯ
http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=720#.VUsJY9rtlBd
Metformin Use May Not Improve Pancreatic Cancer Survival
4/21/2015
PHILADELPHIA ? Metformin use did not improve survival of patients with pancreatic ductal adenocarcinoma (PDAC) in a retrospective cohort study,
according to data presented here at the AACR Annual Meeting 2015, April 18-22. Roongruedee Chaiteerakij, MD, PhD
“The diabetes drug metformin is being used in some cancer treatment trials based on epidemiologic studies that have reported that use of metformin
reduces the risk of death from cancer,” said Roongruedee Chaiteerakij, MD, PhD, of the Division of Gastroenterology and Hepatology
at Mayo Clinic Cancer Center in Rochester, Minnesota. “This study highlights the importance of appropriate design of retrospective studies and
the necessity of conducting prospective studies with solid rationale for determining the effect of diabetes drugs on cancer risk or death.”
According to Chaiteerakij, several epidemiological studies based on retrospective data have reported that metformin is associated with longer survival
from different cancers, including pancreatic cancer. Cancer clinical trials have been opened that incorporate metformin in a treatment arm, in part
based on these studies, but whether metformin has a beneficial effect on improving survival of cancer patients remains unproven.
In this retrospective study to comprehensively assess metformin use and survival, Chaiteerakij and colleagues used data from 1,360 patients with PDAC
who had data available from the Mayo Clinic Specialized Programs of Research Excellence (SPORE) in pancreatic cancer database. Patients were
categorized by metformin use into five groups depending on when they used metformin, from those who had never used metformin to those who started taking
metformin more than 30 days after PDAC diagnosis.
|
|